再鼎医药盘前涨超2.8%,获瑞银给予“买入”评级+近期催化剂明确

格隆汇
Yesterday

再鼎医药(ZLAB.US)盘前涨超2.8%,报26.05美元。消息面上,瑞银近日发表研报,首次覆盖再鼎医药,给予“买入”评级,基于现金流折现法(DCF)对其目标价为33.5港元。瑞银预期集团核心产品VYVGART将持续扩展适应症并提升销售额,同时预期数个重磅候选药物产品将获批;认为ZL-1310(DLL3ADC)及ZL-1503(IL-13/IL-31R)的业务发展(BD)机会,将为近期增长动力;并相信市场似乎忽略了集团短期增长及业务发展潜力。

美股频道更多独家策划、专家专栏,免费查阅>>

责任编辑:山上

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10